EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Colistin Resistance: From Laboratory Research to Modern Clinical Management

Hakan Erdem iD, Gulden Yilmaz-Tehli

Antibiotics · 02.03.2026 · 15 (3) · 259

DOI: 10.3390/antibiotics15030259 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 02.03.2026. Verfasst von Hakan Erdem und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Clinical Microbiology, Gülhane School of Medicine, Health Sciences University, Ankara 06010, Türkiye. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Colistin, a polymyxin antibiotic introduced in the mid-20th century, has regained clinical importance as a last-resort agent for the treatment of infections caused by multidrug-resistant (MDR) Gram-negative bacteria. The global dissemination of carbapenem-resistant pathogens has intensified colistin use, leading to a concerning rise in resistance. This review aims to provide a comprehensive and up-to-date synthesis of colistin’s pharmacological characteristics, resistance mechanisms, epidemiology, and current and emerging therapeutic strategies.

Methods

A narrative review of the literature was conducted, encompassing studies on the chemistry, mechanism of action, pharmacodynamics, clinical use, dosing, and resistance to colistin. Data on chromosomal and plasmid-mediated resistance mechanisms, detection methodologies, epidemiological trends, and clinical outcomes were examined. In addition, evidence on colistin-based treatment strategies and novel non-antibiotic approaches was analyzed.

Results

Colistin remains active against many MDR Gram-negative pathogens, including Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii; however, resistance is increasingly reported worldwide. Both chromosomally mediated modifications of lipid A and plasmid-mediated mcr genes contribute to resistance, with heteroresistance posing diagnostic and therapeutic challenges. Carbapenem resistance has emerged as a major driver of colistin use and subsequent resistance selection. Combination therapies, inhaled formulations, and guideline-directed use may improve outcomes, while emerging alternatives such as antimicrobial peptides, bacteriophages, nanoparticles, photodynamic therapy, and CRISPR-based technologies show promise.

Conclusions

The escalating prevalence of colistin resistance threatens the effectiveness of this critical last-line antibiotic. Optimized use, robust resistance surveillance, accurate detection methods, and the development of innovative therapeutic strategies are essential to preserve colistin’s clinical utility and address the growing burden of MDR Gram-negative infections.

Schlagwörter

Stichwörter der Autor:innen

Klebsiella pneumoniaeantimicrobial resistancecolistinmultidrug-resistant Gram-negative bacteriapolymyxins

Autor:innen und Institutionen

  • Department of Infectious Diseases and Clinical Microbiology, Gülhane School of Medicine, Health Sciences University, Ankara 06010, Türkiye.

ORCID-Profile: Hakan Erdem

Zitieren

APA

Erdem, H., & Yilmaz-Tehli, G. (2026). Colistin Resistance: From Laboratory Research to Modern Clinical Management. Antibiotics, 15(3), 259. https://doi.org/10.3390/antibiotics15030259

Vancouver

Erdem H, Yilmaz-Tehli G. Colistin Resistance: From Laboratory Research to Modern Clinical Management. Antibiotics. 2026;15(3):259. doi:10.3390/antibiotics15030259

BibTeX
@article{Erdem2026,
  author = {Erdem, Hakan and Yilmaz-Tehli, Gulden},
  title = {Colistin Resistance: From Laboratory Research to Modern Clinical Management},
  journal = {Antibiotics},
  year = {2026},
  volume = {15},
  number = {3},
  pages = {259},
  doi = {10.3390/antibiotics15030259}
}
Kostenlos starten →